Navigation Links
AcelRx Pharmaceuticals Reports Third Quarter 2012 Financial Results
Date:11/6/2012

">www.acelrx.com.

Forward Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to AcelRx Pharmaceuticals' financial viability, anticipated increases in research and development and general and administrative expenses, the sufficiency of funds to support its clinical trials and operations, timing of interim and final results of its clinical trials, planned or anticipated future clinical development of AcelRx Pharmaceuticals' product candidates, including the release ARX-01 top-line clinical trial data, the release and anticipated timing of additional ARX-01 clinical trial data, the anticipated timing for remaining clinical trials, and the therapeutic and commercial potential of AcelRx Pharmaceuticals' product candidates.  These forward-looking statements are based on AcelRx Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties.  AcelRx Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: AcelRx ability to raise additional funds to support its clinical trials and operations; the success, cost and timing of AcelRx Pharmaceuticals' product development activities and clinical trials, including timing, release and implications of interim or final results of the ARX-01 Phase 3 clinical trials;  the uncertain clinical development process, including the risk that planned clinical trials may not have an effective design, enroll a sufficient number of patients, or be completed on schedule, if at all; any delays or inability to obtain, regulatory approval of its product candidates; its ability to obtain adequate clinical supplies of the drug and device components of its product candidates; its ability to attract funding partners or collaborators with dev
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. AcelRx Pharmaceuticals Doses the First Patients in ARX-04 Phase 2 Clinical Study
2. AcelRx Pharmaceuticals to Hold Third Quarter 2012 Financial Results Conference Call and Webcast on November 6, 2012
3. AcelRx Pharmaceuticals Hires Mike A. Royal, M.D. as Chief, Clinical Affairs
4. AcelRx Pharmaceuticals to Present at the UBS Global Life Sciences Conference
5. AcelRx Pharmaceuticals Receives Fourth and Fifth U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
6. AcelRx Pharmaceuticals to Present at Three Upcoming Investor Conferences
7. AcelRx Pharmaceuticals Reports Second Quarter 2012 Financial Results
8. AcelRx Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Healthcare Conference
9. AcelRx Pharmaceuticals to Hold Second Quarter 2012 Financial Results Conference Call and Webcast on August 9, 2012
10. AcelRx Pharmaceuticals Receives Two Additional U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
11. AcelRx Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "Investigation Report ... their offering. Originally discovered by Welfide ... Pharmaceutical Industries, Ltd) as an inflammatory drug, pranoprofen ... Pharmaceutical Co., Ltd under the trade name of ...
(Date:8/28/2015)... Utah , Aug. 28, 2015  Today, in ... Prevention,s (CDC) Contact Lens Health Week, 1-800 Contacts is ... has found that contact lens wearers who do not ... greatest risk for eye infections. Most ... their lenses, but a clean lens case is sometimes ...
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "Investigation Report on ... offering. Developed by Pharmacia & Upjohn ... agonist which effectively reduces intraocular pressure. As the ... (under the trade name of Xalatan) entered ...
Breaking Medicine Technology:Investigation Report on China's Pranoprofen Market, 2010-2019 21-800 Contacts Shares Tips on How to Clean Lens Cases 2China Latanoprost Market Investigation Report 2015-2019 2
... FRANKLIN, Tenn., April 13, 2011 In the Journal ... March issue, a comparative research evaluation of five needleless I.V. ... InVision-Plus® (RYM-5001®) zero displacement connector best protected the intraluminal pathway ... The purpose of the study was to evaluate ...
... 12, 2011 Digital Assent founder ... this year,s "Top Up-and-Coming Entrepreneur" award, which will be presented ... from TiE Atlanta, an organization whose mission is to foster ... 2009 Ibbotson founded Digital Assent and launched its flagship product ...
Cached Medicine Technology:According to the Journal of Advanced Nursing, RyMed Technologies' InVision-Plus® Excels at Minimizing Bacterial Growth In Vitro 2Digital Assent CEO Selected as Finalist for 2011 Southeast Entrepreneur Awards 2
(Date:8/29/2015)... ... 2015 , ... Targeted therapies, made possible by a growing ... according to a newly published report. Surviving Mesothelioma has more on the findings ... The authors of the new paper focus on several types of targeted approaches ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... Brands like ... with zero standard shipping costs. , “Before, a threshold of $49.00 was required ... select brands and items qualify for free standard shipping for customers regardless of the ...
(Date:8/29/2015)... Aliso Viejo, CA (PRWEB) , ... August 29, 2015 , ... ... Cut Pro X . Each preset contains 15 seconds of unique footage that users ... presets that rise, fall, zoom, attract and more. Users can customize color, brightness, scale, ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... the localized area with stretching, soft tissue manipulation. Platelet rich plasma injections also ... shown through research to improve treatment outcomes. This localized treatment seems to ...
(Date:8/29/2015)... ... 29, 2015 , ... Vascular Health Sciences announced today that ... Arterosil HP, and that all claims and counterclaims have been irrevocably dismissed. , ... in the United States District Court for the Southern District of Texas for ...
Breaking Medicine News(10 mins):Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3
... Human Settlement Programme, UN-Habitat and cola giant Coca Cola ... to safe drinking water and improved sanitation in India ... ,The project in India will be implemented in West ... non-government organisations (NGOs), the scheme aims at introducing rain ...
... and faculty of Indian origin add to the rich ethnic ... 430 km from here, where a gunman went on a ... of Indian origin. ,Founded in 1872, the Virginia ... called, has more than 25,000 students from as many as ...
... to sign an agreement with the International Vaccine Institute (IVI) ... has given its assent to the move. ,The ... country would now be able to play a role in ... ,The IVI is an International Organization established at the ...
... breast-feeding can negate the risks of breast cancer which are ... of 25. ,The findings of the study ... at the 2007 annual meeting of the American Association for ... may have a protective effect that negates the increased risk ...
... and appearing in today's advance online publication of Nature ... new tool for studying disease mechanisms and for identifying ... disease. ,Both studies were completed by researchers ... Estess Laboratory for Stem Cell Research, the world's first ...
... on arthritis, yet another study says. It neither prevents or ... studies. // ,"We do not have evidence to suggest ... says author Peter Jüni, head of clinical epidemiology and biostatistics ... paper comes a little more than a year after a ...
Cached Medicine News:Health News:Campaign for Safe Drinking Water in India, Nepal 2Health News:Indians Add to Rich Diversity of Virginia Tech 2Health News:Breastfeeding Keeps Breast Cancer At Bay- For Older Mothers 2Health News:Stem Cells Provide New Tool for Studying Disease and Identifying ALS Drugs 2Health News:Chondroitin may Not Have Any Beneficial Effect on Arthritis, New Study Says 2Health News:Chondroitin may Not Have Any Beneficial Effect on Arthritis, New Study Says 3
... Single Use linear stapler with LACTOMER™ ... Suture™ PREMIUM POLY CS™-57 disposable surgical ... of a temporary opening, such as ... section, or when transecting muscle tissue, ...
... Units With Titanium Staples for ... (Single Use Reloadable Stapler with ... Suture™ PREMIUM MULTIFIRE TA™ stapler ... pediatric and thoracic surgical procedures ...
... Single Use Loading Units for ... (Single Use Reloadable Staplers with ... Suture™ TA™ Reloadable staplers has ... and thoracic surgical procedures for ...
... linear stapler for resection, transection and anastomosis ... MULTIFIRE GIA™ 60 and 80 single use ... 80 single use loading units and the ... use surgical stapler with MULTIFIRE SGIA™ 60 ...
Medicine Products: